31,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Alzheimer's disease (AD) is characterized by cognitive decline and loss of neurons in specific brain regions. 4 key findings →
Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
During follow-up 20 SCD and 99 MCI patients developed dementia. 5 key findings →
Participants: 184 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Serum beta-synuclein level was progressively increased in the AD continuum across the preclinical, MCI and dementia stages compared with controls and was correlated with serum pTau181 (r=0.710), NfL (r=0.494) and GFAP concentrations (r=0.621, p<0.001 for all). 5 key findings →
Participants: 56 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Postmortem demonstration of increased expression of biologically active S100B in Alzheimer's disease (AD) and its relation to progression of neuropathological changes across the cortical regions suggests involvement of this astrocytic cytokine in the pathophysiology of AD. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
For the reproducibility, identical P-values and slope estimates were found with both digital biomarkers and neuropsychological test measures between the previous and current studies. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Early-stage Alzheimer's disease (AD) remains difficult to assess using conventional linguistic or cognitive assessments, which often overlook subtle and individualized disruptions in speech. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Digital biomarkers are revolutionizing medicine in ways that were unimaginable a few years ago. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease is the most common dementia in the elderly, and the potential of peripheral biochemical markers as complementary tools in the neuropsychiatric evaluation of these patients has claimed further attention. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
It is not known whether computerized cognitive assessments, like the CogState battery, are sensitive to preclinical cognitive changes or pathology in people at risk for Alzheimer's disease(AD). 4 key findings →
Participants: 71 Evidence: low
Full summary, score breakdown and related studies → Original source
Digital biomarkers are of growing interest in the field of Alzheimer's Disease (AD) research. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
As our knowledge about the biology of Alzheimer's disease (AD) expands and we recognize the significance of early intervention for effective treatment, there is a shift in focus toward detecting the disease at an early stage. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This paper introduces a new deep learning-assisted offline smartphone platform for early AD screening, offering rapid disease detection in low-resource areas. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Monitoring and assessing the progression of symptoms in neurodegenerative diseases, including Alzheimer's and Parkinson's disease, are critical for improving patient outcomes. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Early detection and timely intervention play a vital role in the effective management of Alzheimer's disease. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Facing an unrelenting rise in dementia cases worldwide, researchers are exploring non-pharmacological ways to ameliorate cognitive decline in later life. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) and normal pressure hydrocephalus (NPH) are common forms of dementia in the elderly. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
AcTau174 levels were elevated in all dementia groups compared to controls, with a stepwise increase from controls to MCI-AD (2.2-fold) to AD dementia (3.5-fold, Figure 1). 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The study highlights the potential of integrating 18 F-FDG-PET with CSF biomarkers to improve the diagnosis, prognosis, and monitoring of AD, emphasizing the complexity and regional specificity of biomarker interactions in neurodegeneration. 1 key finding →
Participants: 90 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 42 participants (median age: 71 years, 66.7% female), 26 (61.9%) were classified as progressors. 5 key findings →
Participants: 42 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cognitive assessment and analysis of plasma biomarkers are lower-cost options for the early assessment of Alzheimer's disease (AD). 1 key finding →
Participants: 327 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A total of 156 patients were clinically diagnosed with dementia based on the 2011 NIA-AA criteria, regardless of specific disease etiology, and all exhibited significant brain atrophy on anatomical magnetic resonance imaging (MRI), indicating neuronal injury (N+). 5 key findings →
Participants: 156 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Recent failures of potential novel therapeutics for Alzheimer's disease (AD) have prompted a drive towards clinical studies in prodromal or preclinical states. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The main hypothesis was that subtle vitamin B12 deficiencies occur more commonly in senile dementia of Alzheimer type (SDAT) that in healthy elderly individuals, and may be revealed by elevated total serum homocysteine (tHcy). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Inflammation is believed to play a role in Alzheimer's disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Improvements in leptin and ghrelin levels following bariatric surgery appear to contribute to postoperative cognitive benefits. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,780 records, built mostly from automated pulls of Europe PMC (66% of the library) and OpenAlex (16%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,052 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events